Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Average Price Target of $93.14 According to Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $93.14.

Several brokerages have issued reports on KNSA. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Citigroup increased their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. The Goldman Sachs Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Canaccord Genuity Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th.

Kiniksa Pharmaceuticals International Stock Up 1.4%

Shares of KNSA opened at $80.79 on Tuesday. The business’s 50-day moving average price is $78.13 and its 200-day moving average price is $64.98. Kiniksa Pharmaceuticals International has a twelve month low of $35.20 and a twelve month high of $84.06. The stock has a market cap of $6.30 billion, a PE ratio of 83.29 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The firm had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Analysts expect that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director G. Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Michael Megna sold 4,600 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the sale, the chief accounting officer owned 29,062 shares of the company’s stock, valued at $2,333,678.60. The trade was a 13.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Rubric Capital Management LP lifted its position in Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after buying an additional 421,347 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Kiniksa Pharmaceuticals International by 18.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock worth $39,086,000 after buying an additional 128,417 shares during the period. Spruce Street Capital LP increased its stake in shares of Kiniksa Pharmaceuticals International by 75.0% in the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock worth $36,645,000 after acquiring an additional 326,081 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after acquiring an additional 506,576 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in Kiniksa Pharmaceuticals International by 18.2% in the first quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock worth $30,825,000 after purchasing an additional 98,783 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.